Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AHCO vs NEOG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AHCO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 4–5 Matrix Metrics)
AHCO Overall Winner
6-Pillar Tally: AHCO 3 – 3 NEOG
Matrix Metrics: AHCO 4 – 5 NEOG
As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas NEOG carries 45.2/100 (HOLD) at $10.55 (35.2x Forward P/E, -0.8% operating margin).
- Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile NEOG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AHCO vs NEOG
AHCO
Head-to-Head Winner
AdaptHealth Corp. Common Stock
$7.20
-0.69% 1D
Market Cap
$989.8M
TTM Revenue
$3.44B
Forward P/E
7.8x
Beta / 30D Vol
0.17β · 67% Vol
Unified Composite Score
45.2
HOLD
Tech 29.0
Fund 46.0
Flow 54.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
NEOG
Neogen Corp
$10.55
-2.76% 1D
Market Cap
$2.4B
TTM Revenue
$884M
Forward P/E
35.2x
Beta / 30D Vol
1.35β · 41% Vol
Unified Composite Score
45.2
HOLD
Tech 30.0
Fund 47.0
Flow 56.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (AHCO 3 – 3 NEOG)
1. Valuation Multiples
AHCO
Forward P/E
7.8x
35.2x
Trailing P/E
7.8x
16.0x
PEG Ratio
N/M
0.66x
EV / Revenue
0.9x
3.4x
2. Growth & Scale
AHCO
Revenue Growth (YoY)
+10.9%
+6.5%
Earnings Growth (YoY)
+6.7%
-85.6%
TTM Revenue (USD)
$3.44B
$884M
Market Cap
$989.8M
$2.4B
3. Profitability & Quality
NEOG
Gross Margin
18.2%
47.4%
Operating Margin
3.8%
-0.8%
Net Profit Margin
-11.8%
-6.3%
Return on Equity (ROE)
-28.4%
-2.7%
4. Balance Sheet & Cash Flow
NEOG
Cash Generation (TTM)
$82M
$50M
Cash Flow Margin
2.4%
5.6%
Net Cash / Leverage
$1.97B Net Debt (1.67x D/E)
$602M Net Debt (0.37x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AHCO
Options Structure Phase
SURGE
CONSOLIDATION
Current IV / %ile
66.9% (12th %ile)
46.0% (25th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
NEOG
OpEx & R&D Intensity
14.4% of Rev ($495M)
48.2% of Rev ($426M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AHCO (4) vs NEOG (5)| Institutional Metric | AHCO | NEOG | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $989.8M | $2.4B | NEOG | |
| Trailing P/E Ratio | 7.8x | 16.0x | AHCO | |
| Forward P/E Ratio | 7.8x | 35.2x | AHCO | |
| Revenue Growth (YoY) | +10.9% | +6.5% | AHCO | |
| Operating Margin (TTM) | 3.8% | -0.8% | AHCO | |
| Net Profit Margin | -11.8% | -6.3% | NEOG | |
| Return on Equity (ROE) | -28.4% | -2.7% | NEOG | |
| 52-Week Range Position | 24% ($5–$13) | 58% ($5–$14) | NEOG | |
| Beta / 30D Volatility | 0.17β · 67% Vol | 1.35β · 41% Vol | NEOG | |
| Unified Institutional Score | 45.2 / 100 (HOLD) | 45.2 / 100 (HOLD) | Tie | |
| Trailing 12M Revenue (USD) | $3.44B | $884M | Scale | |
| Gross Profit Margin (TTM) | 18.2% | 47.4% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.9x EV/Rev | 0.66x PEG · 3.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $82M ($1.97B Net Debt (1.67x D/E)) | $50M ($602M Net Debt (0.37x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AHCO +28.63 pp
3M Horizon
AHCO +36.94 pp
6M Horizon
NEOG +49.64 pp
1Y Horizon
NEOG +110.29 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AHCO Revenue | NEOG Revenue | AHCO Op. Margin | NEOG Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $530M | $410M | 5.5% | 16.4% | NEOG |
| FY2020 | $1.06B | $420M | 6.8% | 16.1% | NEOG |
| FY2021 | $2.45B | $470M | 9.2% | 15.8% | NEOG |
| FY2022 | $2.97B | $530M | 6.4% | 11.1% | NEOG |
| FY2023 | $3.20B | $820M | -18.7% | 4.6% | NEOG |
| FY2024 | $3.26B | $920M | 8.1% | 6.3% | AHCO |
| FY2025 | $3.24B | $890M | 2.8% | -118.6% | AHCO |
| FY2026 | N/A | $870M | N/A | -2.5% | NEOG |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AHCO
SURGE
Current IV
66.9%
IV Percentile
12th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
NEOG
CONSOLIDATION
Current IV
46.0%
IV Percentile
25th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NEOG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AHCO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
14.4% of Rev ($495M)
90D Engineering Disclosures
0 Published
NEOG Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
48.2% of Rev ($426M)
90D Engineering Disclosures
0 Published
Investor FAQ AHCO vs NEOG Key Questions & Quantitative Answers
As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Neogen Corp (NEOG) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas NEOG carries 45.2/100 (HOLD) at $10.55 (35.2x Forward P/E, -0.8% operating margin). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile NEOG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AHCO leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with NEOG at +6.5% YoY revenue growth and -85.6% YoY earnings growth on $884M TTM revenue (47.4% gross margin, -0.8% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AHCO cumulative revenue shifted +511.3% while NEOG shifted +112.2%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($426M) (0 disclosures) for NEOG.
AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas NEOG trades at 35.2x Forward P/E, 16.0x Trailing P/E, 0.66x PEG, and 3.4x EV/Revenue (5.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus NEOG (-2.7% ROE) capital efficiency.
In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, NEOG carries 46.0% implied volatility (25th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.35β · 41% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
NEOG vs AHCO · Reverse Pair
AHCO vs OPCH
· Sector Peer
AHCO vs ADUS
· Sector Peer
AHCO vs RPAY
· Sector Peer
NEOG vs MMSI
· Sector Peer
NEOG vs ICUI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem